Precision medicine 2.0: The multiomics era

Did you know that 9 of the top 10 biopharma deals in 2023 involved acquisition targets with a presence in precision medicine? This trend continued in 2024 and has significantly impacted not only pharma companies but also the life sciences tools and labs that support them. The post-genomic era has arrived, and advances in multiomics technologies, including genomics, proteomics, and metabolomics, are enabling us to understand diseases at an unprecedented level and develop targeted therapies that can transform patient care.

Multiomics is the key to unlocking precision medicine because:

• It provides a more complete picture of a patient's physiology, allowing for more accurate and effective diagnostics and therapies.
• The dramatic decrease in the cost of genome sequencing and the application of artificial intelligence (AI) and machine learning have made these technologies more accessible and powerful.
• Integrating data from various omics fields helps researchers uncover novel insights into disease mechanisms and identify new therapeutic targets.

This synergy of advanced technologies and data-driven insights is revolutionizing our understanding of disease mechanisms and opening up new avenues for personalized treatments. Life sciences leaders are investing heavily in this field through mergers and acquisitions, positioning themselves at the forefront of precision medicine.

The strategic focus on multiomics is driving innovation across various disease areas, including oncology, neurodegenerative diseases, and autoimmune disorders, as researchers uncover novel therapeutic targets and develop personalized therapies.

To harness the power of omics technologies for precision medicine, companies should:

• Investigate current portfolios for potential enhancements and expansions, calculating the return on investment for each program.
• Conduct diligence on omics programs using partners or inorganic means to access cutting-edge technologies.
• Develop bespoke multiomics programs and onboard critical AI and omics methodologies in-house and with partners to unlock new therapeutic targets and accelerate drug discovery.

The biggest deals in life sciences tools this year involved proteomics. Precision medicine is shifting to the “post-genomic era”, and pharma companies, life sciences tools companies, and labs must follow suit or risk being left behind. Download our full paper to explore the post-genomic era in greater depth and discover how you can harness the power of integrating omics technologies to establish yourself as a leader in precision medicine.